lipocine

https://www.prnewswire.com/news-releases/lipocine-and-verity-pharma-enter-into-license-agreement-for-tlando-franchise-in-the-us-and-canada-302037718.html SALT LAKE CITY, Jan. 18, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous...

LPCN 1021 is a twice-a-day, oral testosterone product candidate with three simple oral dosing options that we expect will overcome the major shortcomings of existing products. Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced the completion of the last patient...